Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria

Narrative Review: Paroxysmal Nocturnal Hemoglobinuria: The Physiology of Complement-Related Hemolytic Anemia

(2013) Robert A. Brodsky   ANNALS OF INTERNAL MEDICINE

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases

(2011) M. Fridkis-Hareli et al.   BLOOD

Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival

(2011) R. J. Kelly et al.   BLOOD

Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria

(2010) Peter Hillmen et al.   AMERICAN JOURNAL OF HEMATOLOGY

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization

(2010) A. Hill et al.   HAEMATOLOGICA

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab

(2009) A. M. Risitano et al.   BLOOD

How I treat paroxysmal nocturnal hemoglobinuria

(2009) R. A. Brodsky   BLOOD